To investigate the therapeutic potential of hematopoietic cells in regenerative medicine is one of his scientific skill. This highly translational research focused on designing strategies to recruit and program adult stem and progenitor cells to regenerate neovascularization in patients that undergo leg amputation. Currently, his research program is centered around the use of orthotopic humanized adult and pediatric GBM and other metastatic tumor models to evaluate therapeutic potential of standard-of-care cytotoxic agents in combination with small molecular inhibitors that block both the PI3K/Akt/mTOR- and Mdm2-signaling networks. He is investigating the preclinical pharmacokinetic and pharmacodynamics (PK/PD) characteristics of these innovative and unexplored combination treatments at both the molecular and cellular levels with his scientific team. In the context of these therapies, his research lab team is also using in vitro and in vivo screening models to develop intermittent dosing regimens that minimize therapy-mediated hematoxicity.
Subject Areas:
- Molecular Oncology Experimental Therapeutics
